These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9237780)

  • 21. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study.
    Ohkura T; Inoue K; Fujioka Y; Nakanishi R; Shiochi H; Sumi K; Yamamoto N; Matsuzawa K; Izawa S; Ohkura H; Kato M; Yamamoto K; Taniguchi S
    BMC Res Notes; 2013 Nov; 6():453. PubMed ID: 24215809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.
    Güvener N; Gedik O
    Acta Diabetol; 1999 Jun; 36(1-2):93-7. PubMed ID: 10436259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus.
    Rodier M; Richard JL; Monnier L; Mirouze J
    Diabete Metab; 1988; 14(1):12-4. PubMed ID: 3292303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J; Spengler M
    Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea.
    Dworacka M; Abramczyk M; Winiarska H; Kuczynski S; Borowska M; Szczawinska K
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):14-21. PubMed ID: 16425966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system.
    Rosak C; Mertes G
    Curr Diabetes Rev; 2009 Aug; 5(3):157-64. PubMed ID: 19689250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
    Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
    Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment.
    Calle-Pascual AL; Garcia-Honduvilla J; Martin-Alvarez PJ; Vara E; Calle JR; Munguira ME; Marañes JP
    Diabete Metab; 1995 Oct; 21(4):256-60. PubMed ID: 8529760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL; Josse RG; Leiter LA; Mihic M; Nathan DM; Palmason C; Cohen RM; Wolever TM
    Diabetes Care; 1996 Nov; 19(11):1190-3. PubMed ID: 8908378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.
    Pscherer S; Larbig M; von Stritsky B; Pfützner A; Forst T
    J Diabetes Sci Technol; 2012 May; 6(3):634-40. PubMed ID: 22768894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose.
    Scott RS; Knowles RL; Beaven DW
    Aust N Z J Med; 1984 Oct; 14(5):649-54. PubMed ID: 6397178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
    Hermann LS; Ranstam J; Vaaler S; Melander A
    Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acarbose treatment of non-insulin-dependent diabetes mellitus.
    Lardinois CK; Greenfield MS; Schwartz HC; Vreman HJ; Reaven GM
    Arch Intern Med; 1984 Feb; 144(2):345-7. PubMed ID: 6696573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL
    Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters.
    Rosenbaum P; Peres RB; Zanella MT; Ferreira SR
    Braz J Med Biol Res; 2002 Aug; 35(8):877-84. PubMed ID: 12185379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.